摘要
目的初步探讨尼莫地平加依达拉奉在急性脑出血治疗中的临床疗效。方法50例急性脑出血患者随机分为常规治疗组（对照组）和尼莫地平加依达拉奉治疗方案的药物组进行治疗，并于入院后第7、14、21d分别进行血肿体积、水肿容积测量和临床神经功能缺损程度评分（NDS），以及肿瘤坏死因子-α（TNF—α）和神经元特异性烯醇酶（NSE）比较。结果入院后第14、21d药物组血肿体积、水肿容积、TNF—α和NSE浓度明显低于常规治疗组（均P〈0．05）；入院后第21d药物组NDS评分显著低于对照组（P〈0．05）。随着病程的延长2组TNF-α和NSE在血浆中含量逐渐下降，与脑水肿的严重程度密切相关。结论尼莫地平加依达拉奉治疗方案是一种治疗急性脑出血有效、安全的方法；血浆中TNF-α和NSE浓度测定可能作为脑出血疗效评估的客观指标。
Objective Analyze the clinical effect of Nimodipine combined with Edaravone infusion to the patients with acute cerebral hemorrhage. Methods Randomly divided 50 cases of acute cerebral hemorrhage into two groups： the control group provided with routine treatment, and the trail group in which the patients were given infusion of combination of Nimodipine and Edaravone on top of the routine treatment; made comparison of the two groups on the seventh day, the fourteenth day, and the twenty-one day in the areas of volume of hematoma, dimension of edema, clinically neumlogical deficit scales of stroke, the concentration of TNF-α and NSE in the blood plasma. Results The trail group whose volume of hematoma, dimension of edema, the concentration of TNF-α and NSE were significantly reduced after the 14-day treatment in comparison with the control group, while in 21days the trail group whose clinical neurological deficiency score （NDS） were significantly reduced compared with the control group. After the combined treatment of Nimodipine and Edaravone, the concentration of TNF-α and NSF reduced significantly as compared with the control group; the adverse reaction wash＇ t increased in the trail group. Conclusion The combined treatment of Nimodipine and Edaravone may improve the nervous function effectively in patients with acute cerebral hemorrhage, and the concentration of TNF-α and NSF in blood plasma may be an index to evaluate the therapeutic effect of acute cerebral hemorrhage.
出处
《中国急救复苏与灾害医学杂志》
2010年第1期30-32,共3页
China Journal of Emergency Resuscitation and Disaster Medicine
